Initially, Lilly committed $70m to launch the partnership, to fight against multidrug-resistant tuberculosis (MDR-TB) and transfer technology for two Lilly medicines used to treat MDR- TB to other manufacturers.
The additional $30m will help provide training for healthcare providers and improve supply and access to safe, effective and quality-assured second-line drugs.
The company will have committed a total of $165m from 2003-2016 in cash, product and in-kind services and material to The Lilly MDR-TB Partnership and external early drug discovery efforts for TB.